Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 12/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331359 | 0.87 | HPGD (0.56) | HPGDALDH1A1MAPTGAAAOC3 | |
| SCHEMBL10331340 | 0.85 | PRF1 (0.46) | HDAC4HPGDALDH1A1MAPTHSD17B2 | |
| SCHEMBL10332013 | 0.83 | HDAC4 (0.46) | HDAC4HPGDALDH1A1MAPTHSD17B2 | |
| SCHEMBL10331367 | 0.81 | NR3C1 (0.40) | HSD17B2HSD17B1TRPM8 | |
| SCHEMBL25451198 | 0.77 | HDAC6 (0.56) | HPGDMAPTHSD17B2HSD17B1 | |
| SCHEMBL10331361 | 0.76 | PRF1 (0.50) | MAPTRORC | |
| SCHEMBL10331357 | 0.76 | HDAC4 (0.43) | HDAC4HPGDALDH1A1MAPTAOC3 | |
| SCHEMBL14518464 | 0.74 | HDAC4 (0.51) | HDAC4HPGDALDH1A1MAPTPDK2 | |
| SCHEMBL12296890 | 0.74 | APP (0.43) | HSD17B2HSD17B1 | |
| SCHEMBL25094156 | 0.74 | ERN1 (0.47) | HSD17B2HSD17B1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | NR3C1, NFRKB, RELA | HDAC4 1051/4885HPGD 3552/4885ALDH1A1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.